Advertisement
U.S. markets open in 5 hours 45 minutes
Advertisement

Instil Bio, Inc. (TIL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
6.67+0.36 (+5.64%)
At close: 04:00PM EST
6.70 +0.03 (+0.45%)
After hours: 07:13PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close6.31
Open6.20
Bid0.00 x 800
Ask0.00 x 3200
Day's Range6.20 - 6.77
52 Week Range6.08 - 19.80
Volume67,592
Avg. Volume28,357
Market Cap43.381M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-30.20
Earnings DateNov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TIL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

      DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Thursday, December 7, 2023. The Company’s common stock will begin trading on a reverse stock spli

    • GlobeNewswire

      Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

      DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its third quarter 2023 financial results and provided a corporate update. Recent Highlights and Anticipated Milestones: Presented novel preclinical data at SITC 2023 Annual Meeting demonstrating that its CoStimulatory Antigen Receptor (CoStAR)

    • GlobeNewswire

      Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

      Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cellsDALLAS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported two poster presentations at the SITC 2023 Annual Meeting demonstrating that its prop